UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G* (Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. __)*

Coherus Biosciences, Inc.

(Name of Issuer)

Common stock, par value \$0.0001 per share (the "Shares")

(Title of Class of Securities)

19249H103

(CUSIP Number)

May 18, 2023

(Date of Event Which Requires Filing of the Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

□ Rule 13d-1(b)

⊠ Rule 13d-1(c)

□ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	NAME OF REPOR	TINC DED	SONS		
1.	INAME OF REPOR	IING PEK	50115		
	Citadel Advisors L	LC			
2.	2. CHECK THE APP		BOX IF A MEMBER OF A GROUP		
				(a) (b)	
3.	SEC USE ONLY				
4.	CITIZENSHIP OR	PLACE OF	ORGANIZATION		
	Delaware				
		5.	SOLE VOTING POWER		
			0		
Ν	IUMBER OF SHARES	6.	SHARED VOTING POWER		
	SHARES BENEFICIALLY OWNED BY		5,764,907 Shares		
	EACH	7.	SOLE DISPOSITIVE POWER		
R	REPORTING PERSON		0		
	WITH	8.	SHARED DISPOSITIVE POWER		
			See Row 6 above		
9.	AGGREGATE AM	OUNT BEI	NEFICIALLY OWNED BY EACH REPORTING PERSON		
	See Row 6 above				
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				
					0
11.	PERCENT OF CLA	ASS REPRE	ESENTED BY AMOUNT IN ROW (9)		
	6.1% ¹				
12.	TYPE OF REPORT	ING PERS	ON		
	IA; OO; HC				

¹ The percentages reported in this Schedule 13G are based upon 94,017,707 Shares outstanding after completion of the secondary offering and exercise of the over-allotment option (according to the issuer's final prospectus as filed with the Securities and Exchange Commission on May 17, 2023). Except as described in the preceding sentence, all Shares for the holdings of the reporting persons reported in this Schedule 13G are as of the opening of the market on May 19, 2023.

1. NAME OF REPOR		RTING PER	SONS		
	Citadel Advisors I	Holdings L	P		
2.	CHECK THE APP	ROPRIATE	BOX IF A MEMBER OF A GROUP	(a) (b)	
3.	SEC USE ONLY				
4.	CITIZENSHIP OR	PLACE OF	FORGANIZATION		
	Delaware				
	•	5.	SOLE VOTING POWER		
			0		
	NUMBER OF SHARES	6.	SHARED VOTING POWER		
	ENEFICIALLY OWNED BY		5,764,907 Shares		
	EACH REPORTING	7.	SOLE DISPOSITIVE POWER		
	PERSON WITH		0		
	VV1111	8.	SHARED DISPOSITIVE POWER		
			See Row 6 above		
9.	AGGREGATE AM	IOUNT BEI	NEFICIALLY OWNED BY EACH REPORTING PERSON		
	See Row 6 above				
10.	10. CHECK IF THE AGGREG		E AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		0
11.	PERCENT OF CL	ASS REPRI	ESENTED BY AMOUNT IN ROW (9)		
	6.1%				
12.	TYPE OF REPORT	FING PERS	SON		
	PN; HC				

CUSIP No.	19249H103
-----------	-----------

1.	NAME OF REPOR	RTING PER	SONS		
	Citadel GP LLC				
2. CHECK THE APPF		ROPRIATE	BOX IF A MEMBER OF A GROUP		_
				(a) (b)	
3.	SEC USE ONLY				
4.	CITIZENSHIP OR	PLACE OF	FORGANIZATION		
	Delaware				
		5.	SOLE VOTING POWER		
			0		
ľ	NUMBER OF SHARES	6.	SHARED VOTING POWER		
	ENEFICIALLY OWNED BY		5,764,907 Shares		
	EACH REPORTING	7.	SOLE DISPOSITIVE POWER		
	PERSON WITH		0		
	WIIN	8.	SHARED DISPOSITIVE POWER		
			See Row 6 above		
9.	AGGREGATE AM	IOUNT BEI	NEFICIALLY OWNED BY EACH REPORTING PERSON		
	See Row 6 above				
10.	CHECK IF THE A	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			0
11.	PERCENT OF CL	ASS REPRI	ESENTED BY AMOUNT IN ROW (9)		
	6.1%				
12.	TYPE OF REPOR	TING PERS	ON		
	00; HC				

CUSIP No.	19249H103
-----------	-----------

1.	NAME OF REPOI	DTINC DED	SONS		
1.					
Citadel Securities 2. CHECK THE APPH		LLC			
		ROPRIATE	BOX IF A MEMBER OF A GROUP	(a)	0
				(b)	
3.	SEC USE ONLY				
4.	CITIZENSHIP OR	PLACE OF	FORGANIZATION		
	Delaware				
		5.	SOLE VOTING POWER		
			0		
Ν	NUMBER OF SHARES	6.	SHARED VOTING POWER		
	ENEFICIALLY		50,167 Shares		
	OWNED BY EACH	7.	SOLE DISPOSITIVE POWER		
I	REPORTING PERSON		0		
	WITH	8.	SHARED DISPOSITIVE POWER		
			See Row 6 above		
9.	AGGREGATE AN	IOUNT BEI	NEFICIALLY OWNED BY EACH REPORTING PERSON		
51					
10	See Row 6 above	CODECAT			
10.	CHECK IF THE A	GGREGAL	E AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		0
11.	PERCENT OF CL	ASS REPRI	ESENTED BY AMOUNT IN ROW (9)		
	0.1%				
12.	TYPE OF REPOR	TING PERS	ON		
	BD; OO				

CUSIP No.	19249H103
-----------	-----------

1.	NAME OF REPO	RTING PER	SONS			
	Citadel Securities	6 Group LP				
2. CHECK THE APPF		PROPRIATE	BOX IF A MEMBER OF A GROUP			
				(a) (b)		
3.	SEC USE ONLY					
4.	CITIZENSHIP OF	R PLACE OF	FORGANIZATION			
	Delaware					
		5.	SOLE VOTING POWER			
			0			
ľ	NUMBER OF SHARES	6.	SHARED VOTING POWER			
	ENEFICIALLY OWNED BY		50,167 Shares			
	EACH	7.	SOLE DISPOSITIVE POWER			
1	PERSON		0			
	WITH	8.	SHARED DISPOSITIVE POWER			
			See Row 6 above			
9.	AGGREGATE AN	AOUNT BEI	NEFICIALLY OWNED BY EACH REPORTING PERSON			
	See Row 6 above					
10.	CHECK IF THE A	GGREGAT	E AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			
					(
11.	PERCENT OF CL	ASS REPRI	ESENTED BY AMOUNT IN ROW (9)			
	0.1%	0.1%				
12.	TYPE OF REPOR	TING PERS	ON			
	PN; HC					

CUSIP No.	19249H103
-----------	-----------

1.	NAME OF REPOR	RTING PER	SONS		
	Citadel Securities	GP LLC			
2. CHECK THE APPI		ROPRIATE	BOX IF A MEMBER OF A GROUP	()	
				(a) (b)	
3.	SEC USE ONLY				
4.	CITIZENSHIP OR	PLACE OI	FORGANIZATION		
	Delaware				
	·	5.	SOLE VOTING POWER		
			0		
ľ	NUMBER OF SHARES	6.	SHARED VOTING POWER		
	ENEFICIALLY OWNED BY		50,167 Shares		
	EACH	7.	SOLE DISPOSITIVE POWER		
1	PERSON		0		
	WITH	8.	SHARED DISPOSITIVE POWER		
			See Row 6 above		
9.	AGGREGATE AM	IOUNT BEI	NEFICIALLY OWNED BY EACH REPORTING PERSON		
	See Row 6 above				
10.	CHECK IF THE A	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			
					0
11.	PERCENT OF CL	ASS REPRI	ESENTED BY AMOUNT IN ROW (9)		
	0.1%				
12.	TYPE OF REPOR	TING PERS	SON		
	00; HC				

CUSIP No.	19249H103
-----------	-----------

1. NAME OF REPORTING PERSONS					
	Kenneth Griffin				
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				0
3.	SEC USE ONLY				
4.	CITIZENSHIP OR	PLACE OF	FORGANIZATION		
	U.S. Citizen				
		5.	SOLE VOTING POWER		
			0		
	NUMBER OF SHARES	6.	SHARED VOTING POWER		
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH			5,815,074 Shares		
		7.	SOLE DISPOSITIVE POWER		
			0		
		8.	SHARED DISPOSITIVE POWER		
			See Row 6 above		
9.	9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	See Row 6 above				
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
	6.2%				
12.	TYPE OF REPOR	TING PERS	ON		
IN; HC					

CUSIP No. 19249H103		13G	Page 9 of 13 Pages			
Item 1(a).	Name of Issuer:					
	Coherus Biosciences, Inc.					
Item 1(b).	n 1(b). Address of Issuer's Principal Executive Offices:					
	333 Twin Dolphin Drive, Su	ite 600, Redwood City, CA 94065				
Item 2(a).	Name of Person Filing:					
	Citadel GP LLC ("CGP"), C GP LLC ("CSGP") and Mr. "Reporting Persons") with re a Cayman Islands company	jointly filed by Citadel Advisors LLC ("Citadel Advisors") itadel Securities LLC ("Citadel Securities"), Citadel Secur Kenneth Griffin (collectively with Citadel Advisors, CAH, espect to the Shares of the above-named issuer owned by C ("CQ"), Citadel Multi-Strategy Equities Master Fund Ltd., ned Shares may include other instruments exercisable for o	ities Group LP ("CALC4"), Citadel Securities CGP, Citadel Securities, CALC4 and CSGP, the Citadel Quantitative Strategies Master Fund Ltd., a Cayman Islands company ("CM"), and			
	Citadel Advisors is the portfolio manager for CQ and CM. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of Citadel Securities. CSGP is the general partner of CALC4. Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP.					
	The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).					
Item 2(b).	Address or Principal Business Office or, if none, Residence:					
	The address of each of the R	eporting Persons is Southeast Financial Center, 200 S. Bise	cayne Blvd., Suite 3300, Miami, Florida 33131.			
Item 2(c).	Citizenship:					
		GP, Citadel Securities and CSGP is organized as a limited l and CAH is organized as a limited partnership under the la				
Item 2(d).	Title of Class of Securities:					
	Common stock, par value \$0	0.0001 per share				
Item 2(e).	CUSIP Number:					
	19249H103					

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a	Item 3.	If this statement is filed	pursuant to §§ 240.13d	l-1(b), or 240.13d-2(b) or (c), cheo	ck whether the pe	erson filing is a:
--	---------	----------------------------	------------------------	------------------------	----------------	-------------------	--------------------

(a)	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 780);
(b)	Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
(C)	Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the
	Investment Company Act (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
(k)	Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: _____

Item 4. Ownership:

- A. Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC
 - (a) Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 5,764,907 Shares.
 - (b) The number of Shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes 6.1% of the Shares outstanding.
 - (c) Number of Shares as to which such person has:
 - (i) sole power to vote or to direct the vote: 0
 - (ii) shared power to vote or to direct the vote: 5,764,907
 - (iii) sole power to dispose or to direct the disposition of: 0
 - (iv) shared power to dispose or to direct the disposition of: 5,764,907

- (a) Citadel Securities LLC may be deemed to beneficially own 50,167 Shares.
- (b) The number of Shares that Citadel Securities LLC may be deemed to beneficially own constitutes 0.1% of the Shares outstanding.
- (c) Number of shares of Shares as to which such person has:
 - (i) sole power to vote or to direct the vote: 0
 - (ii) shared power to vote or to direct the vote: 50,167
 - (iii) sole power to dispose or to direct the disposition of: 0
 - (iv) shared power to dispose or to direct the disposition of: 50,167
- C. Citadel Securities Group LP and Citadel Securities GP LLC
 - (a) Each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own 50,167 Shares.
 - (b) The number of Shares that each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes 0.1% of the Shares outstanding.
 - (c) Number of Shares as to which such person has:
 - (i) sole power to vote or to direct the vote: 0
 - (ii) shared power to vote or to direct the vote: 50,167
 - (iii) sole power to dispose or to direct the disposition of: 0
 - (iv) shared power to dispose or to direct the disposition of: 50,167

	CUSIP No. 19249H103 D. Kenneth Griffin		3	13G	Page 12 of 13 Pages	
			h Griffin			
		(a)	Mr. Griff	in may be deemed to beneficially own 5,815,074 Shares.		
		(b)	The num outstandi	ber of Shares that Mr. Griffin may be deemed to beneficialling.	y own constitutes 6.2% of the Shares	
	(c) Number			of Shares as to which such person has:		
	(i)		(i)	sole power to vote or to direct the vote: 0		
			(ii)	shared power to vote or to direct the vote: 5,815,074		
			(iii)	sole power to dispose or to direct the disposition of: 0		
			(iv)	shared power to dispose or to direct the disposition of: 5,	815,074	
Item 5.	Item 5. Ownership of Five Percent or Less of a Class:					
				to report the fact that as of the date hereof the reporting pers s of securities, check the following. o	son has ceased to be the beneficial owner of	
Item 6.	em 6. Ownership of More Than Five Percent on Behalf of Another Person:					
	Not Ap	plicable				
Item 7.	Identif Compa		d Classificat	ion of the Subsidiary Which Acquired the Security Bein	g Reported on By the Parent Holding	
	Not Ap	plicable				
Item 8.	Identif	ication and	d Classificat	ion of Members of the Group:		
	Not Ap	plicable				
Item 9.	Notice	of Dissolu	tion of Grou	p:		
	Not Ap	plicable				
Item 10.	Certifi	cations:				
	for the	purpose of	or with the e	, to the best of my knowledge and belief, the securities refer effect of changing or influencing the control of the issuer of participant in any transaction having that purpose or effect.	the securities and were not acquired and are not	

CUSIP No. 19249H103

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated May 19, 2023.

CITADEL SECURITIES LLC

By: /s/ Guy Miller Guy Miller, Authorized Signatory

CITADEL SECURITIES GROUP LP

By: /s/ Guy Miller Guy Miller, Authorized Signatory

CITADEL SECURITIES GP LLC

By: /s/ Guy Miller Guy Miller, Authorized Signatory

CITADEL ADVISORS LLC

By: /s/ Noah Goldberg Noah Goldberg, Authorized Signatory

CITADEL ADVISORS HOLDINGS LP

By: /s/ Noah Goldberg Noah Goldberg, Authorized Signatory

CITADEL GP LLC

By: /s/ Noah Goldberg Noah Goldberg, Authorized Signatory

KENNETH GRIFFIN

By: /s/ Noah Goldberg

Noah Goldberg, attorney-in-fact^{*}

^{*} Noah Goldberg is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Zentalis Pharmaceuticals Inc. on April 9, 2020.

JOINT FILING AGREEMENT

The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Coherus Biosciences, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned.

This Agreement may be executed in counterparts and each of such counterparts taken together shall constitute one and the same instrument.

Dated May 19, 2023.

CITADEL SECURITIES LLC

By: /s/ Guy Miller Guy Miller, Authorized Signatory

CITADEL SECURITIES GROUP LP

By: /s/ Guy Miller Guy Miller, Authorized Signatory

CITADEL SECURITIES GP LLC

By: /s/ Guy Miller Guy Miller, Authorized Signatory

CITADEL ADVISORS LLC

By: /s/ Noah Goldberg Noah Goldberg, Authorized Signatory

CITADEL ADVISORS HOLDINGS LP

By: /s/ Noah Goldberg Noah Goldberg, Authorized Signatory

CITADEL GP LLC

By: /s/ Noah Goldberg Noah Goldberg, Authorized Signatory

KENNETH GRIFFIN

By: /s/ Noah Goldberg

Noah Goldberg, attorney-in-fact^{*}

Noah Goldberg is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and
Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors
LLC on Schedule 13G for Zentalis Pharmaceuticals Inc. on April 9, 2020.